Medical Regulation

The Supreme Court must maintain pregnant people’s right to receive emergency medical care—including abortion.

Australia implements a new framework for regulating the medicinal use of psychedelic substances such as MDMA and psilocybin.

The government should lower regulatory hurdles impeding psilocybin assisted psychotherapy research.

By second-guessing FDA safety determinations, the Fifth Circuit challenges the Supreme Court to restore agency deference.

Experts discuss how regulators can protect consumers from aggressive collection practices.

Anti-abortion advocates take aim at FDA approval and regulation of the abortion drug mifepristone, threatening access nationwide.

FDA’s approach to evidence-based decision-making may not be addressed to the right people.

Experts contend that FDA clinical trials fail to ensure adequate consideration of women’s health needs.

Exploring FDA’s toolkit for encouraging study sponsors to meet diversity goals.

Scholars discuss the lack of uniform standards for health care provided behind bars.

States should require doctors to seek informed consent before performing pelvic exams on anesthetized women.

Federal regulators seek to expand safe harbors for provider care coordination arrangements.